Protalix (PLX) Sells-Off On Pfizer News, As Fast Money Disappointed In No Takeover
Tweet Send to a Friend
Some traders are saying the weakness in Protalix BioTherapeutics (NYSE: PLX) this morning, following a commercialization deal with Pfizer (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
